

GILEAD SCIENCES – 2021 Transfers of Value made to HCPs and HCOs

Date of Publication: 30/6/2022

| | Full Name <i>(Άρθρο 1.01)</i> | HCPs: City of Principal Practice HCOs: city where registered <i>(Άρθρο 3)</i> | Country of Principal Practice <i>(Παράρτημα 1)</i> | Principal Practice Address <i>(Άρθρο 3)</i> | Donations and Grants to HCOs(άρθρο 3.01.1.α) | Contribution to costs of Events <i>(Άρθρα 3.01.1.β & 3.01.2.α)</i> | | | Fee for service and consultancy <i>(Άρθρα. 3.01.1.γ & 3.01.2.β)</i> | | Total Optional |
|---------|--|--|---|--|--|---|-------------------|------------------------|---|---|-------------------|
| | | | | | | Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | |
| ATOMIKA | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | |
| | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | |
| | HCPs | Aggregate amount attributable to transfers of value to such Recipients | | | | | 860,97 | 0,00 | 0,00 | 0,00 | 860,97 |
| | | Number of Recipients in aggregate disclosure | | | | | 2 | 0 | 0 | 0 | 2 |
| | | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed | | | | | 100% | 0% | 0% | 0% | 100% |
| | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | |
| | | | | | | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | |
| | HCOs | Aggregate amount attributable to transfers of value to such Recipients | | | | | | | | | |
| | | Number of Recipients in aggregate disclosure | | | | | | | | | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed | | | | 0% | 0% | 0% | 0% | 0% | 0% | |
| R&D | AGGREGATE DISCLOSURE | | | | | | | | | | |
| | Transfers of Value re Research & Development as defined | | | | | | | | | | 0,00 |